Abstract
Corticotropin-releasing factor (CRF), a 41-amino acid peptide, has been recognized as an important factor mediating stress. Efforts to discover small molecule antagonists of the CRF type-1 receptor (CRF1-R) for potentially novel treatment of anxiety and depression started in the early 1990s. Although highly potent in vitro and efficacious in animal models, early reported compounds such as CP-154,526 and NBI-27914 are highly lipophilic and possess high plasma protein and tissue binding, long elimination half life, and toxicity, likely due in part to accumulation in tissues. Recently, several laboratories have reported potent CRF1-R antagonists with improved physicochemical properties. Compounds such as DMP696, NBI-30775/R121919 and R278995/CRA0450 possess at least one additional polar group in their structures and are therefore less lipophilic than the earlier compounds, while still maintaining high potency. For example, DMP696 has a Ki value of 1.7 nM and a cLogP of 3.2, which is similar to CP-154,526 in potency but about 4-log units lower in partition coefficient. Despite its high plasma protein binding (98.5% in rat), DMP696 occupies over 50% of brain CRF1-R at a total plasma concentration above 100 nM, which is consistent with the doses that produce anxiolytic effects in the rat defense withdrawal test of anxiety. This article will review small molecule CRF1-R antagonists by focusing on their pharmacological and pharmacokinetic properties. In addition, the pharmacology of small molecules binding to the CRF1 receptor will be discussed. An orally available compound with desirable properties in these categories will have a good chance to be developed into a novel treatment for anxiety and depression which may be devoid of the side effects of existing antidepressant treatments.
Keywords: Corticotropin-releasing factor, anxiety and depression, CRF1 receptor, antagonist, insurmountable antagonism, brain concentration, volume of distribution and physicochemical property
Current Medicinal Chemistry
Title: Recent Advances in Small Molecule Antagonists of the Corticotropin- Releasing Factor Type-1 Receptor-Focus on Pharmacology and Pharmacokinetics
Volume: 13 Issue: 11
Author(s): C. Chen
Affiliation:
Keywords: Corticotropin-releasing factor, anxiety and depression, CRF1 receptor, antagonist, insurmountable antagonism, brain concentration, volume of distribution and physicochemical property
Abstract: Corticotropin-releasing factor (CRF), a 41-amino acid peptide, has been recognized as an important factor mediating stress. Efforts to discover small molecule antagonists of the CRF type-1 receptor (CRF1-R) for potentially novel treatment of anxiety and depression started in the early 1990s. Although highly potent in vitro and efficacious in animal models, early reported compounds such as CP-154,526 and NBI-27914 are highly lipophilic and possess high plasma protein and tissue binding, long elimination half life, and toxicity, likely due in part to accumulation in tissues. Recently, several laboratories have reported potent CRF1-R antagonists with improved physicochemical properties. Compounds such as DMP696, NBI-30775/R121919 and R278995/CRA0450 possess at least one additional polar group in their structures and are therefore less lipophilic than the earlier compounds, while still maintaining high potency. For example, DMP696 has a Ki value of 1.7 nM and a cLogP of 3.2, which is similar to CP-154,526 in potency but about 4-log units lower in partition coefficient. Despite its high plasma protein binding (98.5% in rat), DMP696 occupies over 50% of brain CRF1-R at a total plasma concentration above 100 nM, which is consistent with the doses that produce anxiolytic effects in the rat defense withdrawal test of anxiety. This article will review small molecule CRF1-R antagonists by focusing on their pharmacological and pharmacokinetic properties. In addition, the pharmacology of small molecules binding to the CRF1 receptor will be discussed. An orally available compound with desirable properties in these categories will have a good chance to be developed into a novel treatment for anxiety and depression which may be devoid of the side effects of existing antidepressant treatments.
Export Options
About this article
Cite this article as:
Chen C., Recent Advances in Small Molecule Antagonists of the Corticotropin- Releasing Factor Type-1 Receptor-Focus on Pharmacology and Pharmacokinetics, Current Medicinal Chemistry 2006; 13 (11) . https://dx.doi.org/10.2174/092986706776873014
DOI https://dx.doi.org/10.2174/092986706776873014 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Bullying Prevention Plan: An Approach to Youth who Bully Others
Adolescent Psychiatry Tau Truncation is a Productive Posttranslational Modification of Neurofibrillary Degeneration in Alzheimer’s Disease
Current Alzheimer Research Regulatory Mechanisms of Calcineurin Phosphatase Activity
Current Medicinal Chemistry The Effect of Liver Cirrhosis on the Regulation and Expression of Drug Metabolizing Enzymes
Current Drug Metabolism Viral Carcinogenesis of Oral Region and Recent Trends in Treatment
Recent Patents on Biomarkers Role of Topological, Electronic, Geometrical, Constitutional and Quantum Chemical Based Descriptors in QSAR: mPGES-1 as a Case Study
Current Topics in Medicinal Chemistry Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology Lysosomotropic Drugs: Pharmacological Tools to Study Lysosomal Function
Current Drug Metabolism Neuronal Death and Survival Under Oxidative Stress in Alzheimer and Parkinson Diseases
CNS & Neurological Disorders - Drug Targets Effects of Fluoxetine and Venlafaxine and Pilocarpine on Rat Parotid Glands
Medicinal Chemistry Novel Technologies for Dipeptide Drugs Design and their Implantation
Current Pharmaceutical Design HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): Still an Obscure Disease
Central Nervous System Agents in Medicinal Chemistry Exploration of Psychological Well-Being, Resilience, Ethnic Identity, and Meaningful Events Among a Group of Youth in Northern England: An Autobiographical Narrative Intervention Pilot Study
Adolescent Psychiatry Early Timing of Endovascular Treatment for Aneurysmal Subarachnoid Hemorrhage Achieves Improved Outcomes
Current Neurovascular Research An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Age-Related Pharmacokinetic and Pharmacodynamic Changes and Related Risk of Adverse Drug Reactions
Current Medicinal Chemistry Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade
CNS & Neurological Disorders - Drug Targets Polyunsaturated Fatty Acids and their Related Enzymes in Postmortem Brain Tissues of Patients with Psychiatric Disorders
Current Psychopharmacology